Infect Dis Clin North Am. 2021 Jun;35(2):435-452. doi: 10.1016/j.idc.2021.03.009.
ABSTRACT
Mucormycosis is a rare but aggressive fungal disease that mainly affects patients with poorly controlled diabetes mellitus and those who are severely immunocompromised, including patients with hematological malignancies and solid organ transplant recipients. Early recognition of infection is critical for treatment success, followed by prompt initiation of antifungal therapy with lipid formulation amphotericin B. Posaconazole and isavuconazole should be used for stepdown and salvage therapy. Surgical debridement is key for tissue diagnosis and treatment and should be pursued urgently whenever possible. In addition to surgery and antifungal therapy, reverting the underlying risk factor for infection is important for treatment response.
PMID:34016285 | DOI:10.1016/j.idc.2021.03.009
can some one send me the article
With the current COVID-19 associated mucor outbreak in India, maybe publishers will make articles like this open-access like they do other COVID-19 articles. In the meantime, StatPearls has a good recent review here that should be open-access: https://www.ncbi.nlm.nih.gov/books/NBK557429/